---
title: "Johnson & Johnson $JNJ Stake Lessened by Van Hulzen Asset Management LLC"
description: "Van Hulzen Asset Management LLC reduced its stake in Johnson & Johnson (NYSE: JNJ) by 22.5% in Q1, now holding 118,842 shares valued at approximately $19.7 million. Other investors, including Brighton"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254279828.md"
published_at: "2025-08-23T13:28:47.000Z"
---

# Johnson & Johnson $JNJ Stake Lessened by Van Hulzen Asset Management LLC

> Van Hulzen Asset Management LLC reduced its stake in Johnson & Johnson (NYSE: JNJ) by 22.5% in Q1, now holding 118,842 shares valued at approximately $19.7 million. Other investors, including Brighton Jones LLC and Hudson Value Partners LLC, have also adjusted their positions. JNJ shares opened at $178.90, with a 12-month range of $140.68 to $180.61. The company reported Q2 earnings of $2.77 per share, exceeding estimates, and announced a quarterly dividend of $1.30, yielding 2.9%.

Van Hulzen Asset Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 22.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,842 shares of the company's stock after selling 34,558 shares during the period. Johnson & Johnson comprises approximately 1.8% of Van Hulzen Asset Management LLC's portfolio, making the stock its 12th biggest position. Van Hulzen Asset Management LLC's holdings in Johnson & Johnson were worth $19,709,000 at the end of the most recent quarter.

-   JNJ Stock Surge Signals Confidence in New Growth Path

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares during the period. Hudson Value Partners LLC increased its stake in shares of Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Burling Wealth Partners LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at $3,908,000. Integrated Wealth Concepts LLC grew its stake in Johnson & Johnson by 6.1% in the fourth quarter. Integrated Wealth Concepts LLC now owns 108,473 shares of the company's stock valued at $15,687,000 after purchasing an additional 6,247 shares in the last quarter. Finally, Empire Financial Management Company LLC increased its position in Johnson & Johnson by 18.0% in the 4th quarter. Empire Financial Management Company LLC now owns 17,882 shares of the company's stock worth $2,586,000 after purchasing an additional 2,732 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Get **Johnson & Johnson** alerts:

## Johnson & Johnson Stock Performance

Shares of JNJ opened at $178.8990 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $180.61. The company's fifty day moving average is $163.04 and its 200-day moving average is $159.05. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $430.85 billion, a price-to-earnings ratio of 19.13, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41.

-   3 Big Dividend Plays With Strong Earnings to Back Them

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the business posted $2.82 EPS. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

## Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

## Analyst Upgrades and Downgrades

-   Worried About a Fading Rally? Consider These 3 Dividend Stocks

Several equities research analysts recently commented on the company. Barclays boosted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Guggenheim restated a "neutral" rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $176.29.

**Get Our Latest Stock Analysis on JNJ**

## About Johnson & Johnson

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

## Further Reading

-   Five stocks we like better than Johnson & Johnson
-   How to start investing in penny stocks
-   Small Cap, Big Potential: 3 Tech Disruptors You Should Know About
-   Conference Calls and Individual Investors
-   After Earnings Miss, Walmart Is Still a Top Consumer Staples Play
-   High Dividend REITs: Are They an Ideal Way to Diversify?
-   How Cisco Is Building a New Growth Story for Investors

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [JNJ.US - Johnson & Johnson](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Could This Single Dividend King Make Your Portfolio Worth $1 Million in 20 Years? | Johnson & Johnson (JNJ) is a leading healthcare company known for its 62 consecutive years of dividend increases. Despit | [Link](https://longbridge.com/en/news/259050773.md) |
| Wealth Advisory Team LLC Buys Shares of 1,548 Johnson & Johnson $JNJ | Wealth Advisory Team LLC acquired 1,548 shares of Johnson & Johnson (NYSE: JNJ) during Q2, valued at approximately $236, | [Link](https://longbridge.com/en/news/261200197.md) |
| Short Interest in Garmin Ltd. (NYSE:GRMN) Increases By 33.2% | Garmin Ltd. (NYSE:GRMN) experienced a 33.2% increase in short interest in January, totaling 3,028,012 shares as of Janua | [Link](https://longbridge.com/en/news/276018254.md) |
| Codeifai Enters AI-Backed Quantum Security Market | Codeifai Ltd :CODEIFAI ENTERS AI-BACKED QUANTUM SECURITY MARKETCOMPLETION OF ACQUISITION OF ANTENNATRANSFER.IOTOTAL CONS | [Link](https://longbridge.com/en/news/276015719.md) |
| Did Analyst Upgrades and Metal Price Tailwinds Just Shift Coeur Mining's (CDE) Investment Narrative? | Recent analyst upgrades for Coeur Mining, alongside rising gold and silver prices, have shifted focus on the company's c | [Link](https://longbridge.com/en/news/275995095.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
